Vivos TherapeuticsVVOS +6.47%41 EV-to-FCF is -0.85 as of Jul. 07, 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Vivos Therapeutics ranks worse than 239807.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vivos Therapeutics's Enterprise Value is $16.73 Mil.
Vivos Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-19.71 Mil. Therefore, Vivos Therapeutics's EV-to-FCF for today is -0.85.
The historical rank and industry rank for Vivos Therapeutics's EV-to-FCF or its related term are showing as below:
VVOS'
s EV-to-FCF Range Over the Past 10 Years
Min: -43.26 Med: -1.29 Max: -0.14
Current: -0.85
During the past 8 years, the highest EV-to-FCF of Vivos Therapeutics was -0.14. The lowest was -43.26. And the median was -1.29.
VVOS's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.54
vs VVOS: -0.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vivos Therapeutics's PE Ratio (TTM) for today is calculated as:
Vivos Therapeutics's share price for today is $0.478.
Vivos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vivos Therapeutics EV-to-FCF Related Terms
Vivos Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's EV-to-FCF falls into.
Vivos Therapeutics's current Enterprise Value is $16.73 Mil.
Vivos Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivos Therapeutics (VVOS) has a EV-to-FCF of -0.85 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vivos Therapeutics and its competitors. According to the industry distribution chart, Vivos Therapeutics ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Vivos Therapeutics' EV-to-FCF too high?
Vivos Therapeutics' current EV-to-FCF is -0.85. Based on the distribution chart, Vivos Therapeutics ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' EV-to-FCF compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #999999 out of 417 companies for EV-to-FCF. This places Vivos Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 23.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.54, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current EV-to-FCF is -0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.48 — trading 58.4% below its estimated fair value. The current EV-to-FCF is -0.85. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current EV-to-FCF is -0.85 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.48 is trading 58.4% below its estimated GF Value™ of $1.15.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
EV-to-FCF: -0.85
GF Value™: $1.15 vs. price of $0.48 (58.4% below fair value)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score
Get the complete analysis for VVOS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
